Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xenon
Biotech
Xenon pauses ph. 3 depression trials after psychosis events
The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.
Nick Paul Taylor
Sep 18, 2026 6:03am
Xenon epilepsy candidate 'blows away' ph. 3 expectations
Mar 9, 2026 10:55am
Biotech’s top 5 stock picks for 2026: analyst
Dec 23, 2025 10:05am
Xenon's MDD med fails ph. 2, elevating seizure potential
Nov 27, 2023 10:45am
Double whammy for Neurocrine as Takeda, Xenon pacts fail
Nov 10, 2023 7:22am
Biohaven veers toward Kv7 platform following Pfizer sale
Oct 4, 2022 11:48am
